Introduction {#s1}
============

Patients with pulmonary embolism (PE) who are at extremes of body weight pose specific clinical considerations with regard to diagnosis, treatment and prognosis. Patients who are obese are at increased risk for both deep vein thrombosis (DVT) and PE compared to patients with a normal body mass index (BMI; weight in kilograms divided by height in metres squared) \[[@C1]--[@C3]\]. This risk increases with increasing BMI \[[@C4], [@C5]\]. Potential causal mechanisms for increased risk of venous thrombosis by obesity are venous stasis, chronic inflammation, adipokines, increased coagulation activity, decreased fibrinolytic activity, and procoagulant microparticles \[[@C6]\].

Regarding treatment, it is debated whether the patients at extremes in body weight should receive modified treatment regimens \[[@C7]\]. Because of limited clinical data available for patients who are obese, the International Society on Thrombosis and Haemostasis (ISTH) guidance document advises against the use of direct oral anticoagulants in patients with a body weight higher than 120 kg or a BMI higher than 40 \[[@C8]\]. Although currently unfractioned heparin with activated partial thromboplastin time monitoring for patients with severe obesity is recommended \[[@C9]\], an expert panel recently expressed the urgent need for data on heparin regimens in all patients who are obese \[[@C7]\]. This becomes even more prominent with the alarming increase in people who are overweight worldwide \[[@C10]\].

Remarkably, with regard to diagnosis and prognosis, knowledge of the impact of BMI on clinical presentation and clot characteristics and burden is even more limited. Unfortunately, even in large randomised trials on efficacy of anticoagulation in patients with venous thromboembolism (VTE) no subgroup analysis on body weight or BMI has been performed to provide methodologically robust data on this subject. Therefore, how this could reflect on work-up and prognosis is not exactly known. Should BMI be a modifier for individual patient-tailored care? Does body size matter?

Our hypothesis was that in patients with PE clot characteristics and prognosis are different at the extremes of BMI. The aim of this study was to explore the impact of body size on presentation, prognostic characteristics and outcome of patients with PE in computed tomography (CT) pulmonary angiography (CTPA). Therefore, we studied in a large cohort of patients with PE established clinical and radiological parameters associated with right ventricular dysfunction and mortality, and stratified them according to BMI categories.

Materials and methods {#s2}
=====================

Patients and study design {#s2a}
-------------------------

This present study is a *post hoc* analysis of the Hokusai VTE study, a large international randomised clinical trial in which two anticoagulant regimens were compared in patients with VTE (ClinicalTrials.gov identifier: NCT00986154) \[[@C11], [@C12]\]. In short, eligible patients were aged 18 years or older and had acute symptomatic DVT and/or PE. Patients were excluded in case of contraindication to heparin or warfarin, severely impaired renal function or pregnancy. The Hokusai VTE trial did not exclude patients based on body weight. The institutional review board at each participating centre approved the general study protocol, and all patients provided written informed consent. Follow-up was 12 months, covering the in-hospital period as well as regular outpatient clinic controls, and patients on and off anticoagulant treatment. Adverse events were noted on separate forms, as well as whether these were related to PE. An independent committee adjudicated all predefined outcomes. In the trial, in the two treatment arms there was no difference in hazard ratio between patients with a body weight of 100 kg or less, and those over 100 kg; no further detailed analyses were performed for high body weight groups \[[@C11]\]. For the current analysis all patients with PE, either with or without DVT, were included. Excluded were patients not evaluated by CTPA, or when images were not available in DICOM format or inaccessible for reading in the image viewer \[[@C12]\].

Data collection {#s2b}
---------------

All clinical and radiological data were anonymised, and centrally registered with double data entry by an independent trial data management agency. Clinical data were retrieved from the original case report form (CRF). In all patients NT-proBNP levels were measured at baseline. All data for the present analysis had been collected and assessed prospectively before the trial data lock.

CT data were acquired from the local participating centres, using local settings and protocols, with a wide variety of CT scanners, from basic to high-end CT. Anonymised patient images from the central database were evaluated by a radiologist (LB) with 12 years of experience in cardiovascular imaging supported by a dedicated research assistant, both blinded for patient details and clinical information. For image reading a commercially available image viewer was used (eFilm Workstation for Windows version 3.4.0, Build 10, Merge Technologies Inc., Milwaukee, WI, USA). Images were primarily read in axial sections with additional support of multiplanar reformatting. Standard pulmonary angiography, mediastinal and lung parenchyma window settings were used, with individual adaptation if deemed necessary. Data were registered on a specially designed CRF.

We investigated body size according to the BMI categories as classified by the World Health Organization (WHO): underweight (\<18.5), normal (18.5 to \<25), overweight (25 to \<30), obese I (30 to \<35), obese II (35 to \<40), and obese III (≥40).

Study outcomes: prognostic characteristics and clinical outcomes {#s2c}
----------------------------------------------------------------

Both clinical and radiological prognostic characteristics for right ventricular dysfunction and adverse events were assessed. For baseline NT-proBNP a value of ≥600 pg·mL^−1^ at baseline was considered abnormal \[[@C9]\]; for sPESI calculations the arterial oxyhaemoglobin saturation \<90% was not registered; this item was considered positive if patient required oxygen administration. The following radiological parameters for right ventricular dysfunction (RVD) were assessed: transverse diameter of the right and left ventricle (axial view) and pulmonary trunk (PT); bowing of the interventricular septum (negative, D-shaped/neutral, positive) and reflux of contrast medium in the intrahepatic veins). For the ventricular diameters, the largest cross-sectional distance between ventricular surfaces was taken. The PT was measured at its largest transverse diameter. All continuous variables were noted in millimetres where applicable. The right-to-left ventricular (RV/LV) ratios were calculated by dividing the values of respective transverse diameters. The obtained values were then dichotomised at regular used thresholds (RV/LV\>1.0; PT \>29 mm). Interventricular septum bowing was considered present when the septum was curved to the left ventricle or flattened. Backflow was considered positive if contrast medium reflux occurred into the intrahepatic veins; only into the inferior caval vein was considered negative.

Clinical outcomes for the study were mortality, recurrent VTE, hospitalisation, bleeding and overall adverse events. Outcome events were analysed after a follow-up of 1 year.

Statistical analysis {#s2d}
--------------------

Descriptive statistics are displayed as mean±[sd]{.smallcaps} for normally distributed variables and median±interquartile ranges (IQR, 25th to 75th percentile) for non-normally distributed variables. For comparison of binary outcomes, the Chi-squared test for dichotomous variables was used. Between the groups, categorical variables were compared using the Chi-squared test for trend and for continuous data, by t-test or Mann--Whitney U-test if non-normally distributed. A p-value\<0.05 was considered statistically significant. We used logistic regression models to estimate odds ratios (ORs) with 95% confidence intervals (CIs) to investigate the association between the outcome variables and the BMI categories. In addition, where appropriate, we adjusted these analyses for age and sex. All statistical analyses were performed in SPSS version 23 (SPSS Inc., Chicago, IL, USA) and figures were designed in GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla California, CA, USA).

Results {#s3}
=======

Baseline characteristics are displayed in [table 1](#TB1){ref-type="table"}. The initial study group consisted of 1950 patients with PE. In all 1950 patients, baseline weight was available, but in 39 patients (2.0%) body height was not known. Hence baseline BMI could only be calculated in 1911 patients, comprising the study group for further analyses. Of these 1911 patients, 493 (25.8%) had a normal BMI ([table 2](#TB2){ref-type="table"}). The majority of patients (1389; 72.7%) had a BMI\>25 and obesity (BMI\>30) was present in 670 (35.1%) patients. A small proportion of patients (29; 1.5%) was underweight. TABLE 1Baseline characteristics**TotalBMI \<18.5 kg·m^−2^BMI 18.5--24.99 kg·m^−2^BMI \>25 kg·m^−2^Included**1911 (100%)29 (1.5%)493 (25.8%)1389 (72.7%)**Clinical** Age years56.9±16.656.6±23.955.7±18.857.3±15.5 Weight kg84.6±20.149.9±8.066.7±10.091.7±18.2 SBP mmHg128±16.5118±15.4126±16.8129±16.3 DBP mmHg76±11.069±8.874±10.677±11.1 Heart rate beats per min80±14.285±10.080±14.780±14.1 Age \<50 years629 (32.9%)11 (37.9%)190 (38.5%)428 (30.8%) Age \>65 years696 (36.4%)14 (48.3%)183 (37.1%)499 (35.9%) Weight \<60 kg187 (9.8%)24 (82.8%)144 (29.2%)19 (1.4%) Current alcohol use741 (38.8%)10 (34.5%)199 (40.4%)532 (38.3%) Smoking834 (43.6%)15 (51.7%)235 (47.7%)584 (42.0%) NT-proBNP \>600 pg·mL^−1^504 (27.3%)12 (42.9%)115 (23.9%)377 (28.2%) sPESI^\#^ high risk ≥11028 (53.8%)21 (72.4%)251 (50.9%)756 (54.4%) Unprovoked PE1266 (66.2%)21 (72.4%)327 (66.3%)918 (66.1%) Concurrent DVT447 (23.4%)3 (10.3%)102 (20.7%)342 (24.6%)**Risk factors** Recent surgery, trauma or immobilisation364 (19.0%)5 (17.2%)76 (15.4%)283 (20.4%) Sitting \>4 h182 (9.5%)1 (3.4%)58 (11.8%)123 (8.9%) Oestrogen drug use193 (10.1%)8 (27.6%)73 (14.8%)112 (8.1%) Previous DVT/PE405 (21.2%)1 (3.4%)85 (17.2%)319 (23.0%) Thrombophilia94 (4.9%)1 (3.4%)32 (6.5%)61 (4.4%)**Concomitant disease history** Hypertension793 (41.5%)11 (37.9%)136 (27.6%)646 (46.5%) Diabetes194 (10.2%)3 (10.3%)18 (3.7%)173 (12.5%) Cardiovascular disease306 (16.0%)6 (20.7%)82 (16.6%)218 (15.7%) Chronic heart failure34 (1.8%)2 (6.9%)6 (1.2%)26 (1.8%) Cerebrovascular disease71 (3.7%)1 (3.4%)20 (4.1%)50 (3.6%) Stroke34 (1.8%)1 (3.4%)11 (2.2%)22 (1.6%) Renal disease128 (6.7%)2 (6.9%)30 (6.1%)96 (6.9%) Hepatic disease207 (10.8%)3 (10.3%)47 (9.5%)157 (10.8%) Pulmonary disease391 (20.5%)12 (41.4%)91 (18.5%)288 (20.7%) COPD100 (5.2%)7 (24.1%)35 (7.1%)58 (4.2%) Pulmonary hypertension43 (2.3%)2 (6.9%)6 (1.2%)35 (2.5%) Cancer221 (11.6%)6 (20.7%)65 (13.2%)150 (10.8%)Data are presented as mean±[sd]{.smallcaps} unless otherwise stated. SBP: systolic blood pressure; DBP: diastolic blood pressure; NT-proBNP: N-terminal pro-brain natriuretic peptide; sPESI: simplified Pulmonary Embolism Severity Index; PE: pulmonary embolus; DVT: deep vein thrombosis. ^\#^: item on oxygen considered positive if patient needed oxygen administration. TABLE 2Distribution of patients according to World Health Organization body mass index (BMI) categories (N=1911)**BMI \<18.5 kg·m^−2^**29 (1.5%)**BMI 18.5--24.9 kg·m^−2^**493 (25.8%)**BMI 25--29.9 kg·m^−2^**717 (37.5%)**BMI 30--34.9 kg·m^−2^**414 (21.7%)**BMI 35--39.9 kg·m^−2^**154 (8.1%)**BMI ≥40 kg·m^−2^**104 (5.4%)**Complete**1950^\#\#^: body height was not available in 39 (2.0%) out of 1950 patients so in these patients, BMI could not be calculated.

With regard to risk factors for VTE, 372 patients (19.5%) had undergone recent surgery and 415 patients (21.7%) had a history of VTE. Arterial cardiovascular risk factors (*e.g.* smoking and hypertension) were present in a substantial proportion of patients: hypertension was present in 810 (42.4%) patients, 199 (10.4%) patients had diabetes mellitus, and 314 (16.4%) patients had a history of cardiovascular disease.

The overall trend, clinical, radiological and outcome parameters are displayed in [figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"} for all patients according to the BMI categories. Both patterns for N-terminal pro-brain natriuretic peptide (NT-proBNP), PE severity index (sPESI) and enlarged PT showed a U-shaped curve, with lowest percentages in the normal BMI range, and were higher for patients who were overweight as well as underweight. Other parameters such as enlarged RV/LV ratio and central clot location showed a direct association with increasing BMI.

![Association between body mass index (BMI) categories and clinical and radiological parameters with BMI 18.5--24.9 kg·m^−2^ as a reference. Odds ratios for a) N-terminal pro-brain natriuretic peptide, b) high-risk simplified pulmonary embolism severity index score, c) pulmonary trunk \>29 mm, d) right/left ventricular diameter ratio \>1.0, e) central embolism and d) concurrent deep venous thrombosis are shown. Error bars present 95% confidence intervals.](00163-2019.01){#F1}

![Association between body mass index (BMI) categories and outcomes with BMI 18.5--24.9 kg·m^−2^ as reference. Odds ratios for a) death, b) recurrent venous thromboembolism, c) hospitalisation, d) bleeding and e) all adverse events are shown. Error bars represent 95% confidence intervals.](00163-2019.02){#F2}

The associations between the prognostic characteristics and BMI categories are shown in [table 3](#TB3){ref-type="table"} and detailed distribution of parameters and outcomes in [supplementary table 4](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00163-2019.figures-only#fig-data-supplementary-materials). There was an apparent exposure--response relationship between BMI category and the proportion of patients with NT-proBNP \>600, sPESI high risk, PT \>29 mm, RV/LV\>1 and presence of central emboli. The OR for NT-proBNP \>600 increased up to 2.90 (95% CI 1.79--4.70) at BMI\>40. For the other prognostic characteristics the ORs for BMI\>40 compared to normal BMI were OR 4.32 (95% CI 2.73--6.83) for PT \>29 mm, 2.12 (95% CI 1.34--3.33) for RV/LV\>1.0, 2.34 (95% CI 1.51--3.62) for central location of the emboli and 1.55 (95% CI 1.00--2.41) for the sPESI high risk category.

###### 

Odds ratios for clinical and radiological parameters and outcomes according to World Health Organization body mass index (BMI) categories

                                              **Patients**   **Unadjusted OR (95% CI)**   **Adjusted^\#^ OR (95% CI)**
  ------------------------------------------ -------------- ---------------------------- ------------------------------
  **Clinical and radiological parameters**                                               
   NT-proBNP \>600 pg·mL^−1^                                                             
    BMI \<18.5 kg·m^−2^                        12 (42.8%)        2.38 (1.09--5.18)             2.62 (1.10--6.23)
    BMI 18.5--24.9 kg·m^−2^                   115 (24.0%)             1 (ref.)                      1 (ref.)
    BMI 25.0--29.9 kg·m^−2^                   162 (23.4%)        0.97 (0.74--1.28)             0.98 (0.74--1.31)
    BMI 30.0--34.9 kg·m^−2^                   124 (31.2%)        1.44 (1.07--1.94)             1.41 (1.03--1.93)
    BMI 35.0--39.9 kg·m^−2^                    50 (34.0%)        1.64 (1.10--2.44)             1.62 (91.06--2.48)
    BMI \>40 kg·m^−2^                          41 (41.0%)        2.21 (1.41--3.46)             2.90 (1.79--4.70)
   sPESI high risk                                                                       
    BMI \<18.5 kg·m^−2^                        21 (72.4%)        2.52 (1.10--5.80)             2.49 (1.08--5.75)
    BMI 18.5--24.9 kg·m^−2^                   251 (51.0%)             1 (ref.)                      1 (ref.)
    BMI 25.0--29.9 kg·m^−2^                   375 (52.4%)        1.06 (0.84--1.33)             1.11 (0.88--1.40)
    BMI 30.0--34.9 kg·m^−2^                   230 (55.7%)        1.21 (0.93--1.57)             1.23 (0.95--1.60)
    BMI 35.0--39.9 kg·m^−2^                    84 (54.5%)        1.15 (0.80--1.66)             1.13 (0.78--1.62)
    BMI \>40 kg·m^−2^                          66 (63.5%)        1.67 (1.08--2.58)             1.55 (1.00--2.41)
   Pulmonary trunk \>29 mm                                                               
    BMI \<18.5 kg·m^−2^                        8 (27.6%)         1.39 (0.60--3.22)             1.36 (0.56--3.28)
    BMI 18.5--24.9 kg·m^−2^                   106 (21.5%)             1 (ref.)                      1 (ref.)
    BMI 25.0--29.9 kg·m^−2^                   232 (32.4%)        1.75 (1.34--2.28)             1.66 (1.27--2.19)
    BMI 30.0--34.9 kg·m^−2^                   168 (40.7%)        2.50 (1.87--3.34)             2.44 (1.81--3.28)
    BMI 35.0--39.9 kg·m^−2^                    59 (38.3%)        2.26 (1.53--3.34)             2.37 (1.59--3.53)
    BMI \>40 kg·m^−2^                          49 (47.1%)        3.24 (2.09--5.04)             4.32 (2.73--6.83)
   RV/LV \>1.0                                                                           
    BMI \<18.5 kg·m^−2^                        4 (13.8%)         0.45 (0.15--1.31)             0.40 (0.13--1.12)
    BMI 18.5--24.9 kg·m^−2^                   130 (26.4%)             1 (ref.)                      1 (ref.)
    BMI 25.0--29.9 kg·m^−2^                   231 (32.3%)        1.33 (1.03--1.71)             1.31 (1.01--1.70)
    BMI 30.0--34.9 kg·m^−2^                   157 (38.0%)        1.71 (1.29--2.27)             1.66 (1.24--2.21)
    BMI 35.0--39.9 kg·m^−2^                    48 (31.2%)        1.26 (0.85--1.88)             1.24 (0.83--1.85)
    BMI \>40 kg·m^−2^                          41 (39.4%)        1.81 (1.17--2.81)             2.12 (1.34--3.33)
   Central embolus                                                                       
    BMI \<18.5 kg·m^−2^                        7 (24.1%)         0.78 (0.33--1.86)             0.75 (0.31--1.82)
    BMI 18.5--24.9 kg·m^−2^                   143 (29.1%)             1 (ref.)                      1 (ref.)
    BMI 25.0--29.9 kg·m^−2^                   234 (32.7%)        1.19 (1.19--0.92)             1.17 (0.91--1.50)
    BMI 30.0--34.9 kg·m^−2^                   167 (40.4%)        1.66 (1.26--2.19)             1.61 (1.22--2.13)
    BMI 35.0--39.9 kg·m^−2^                    62 (40.3%)        1.65 (1.30--2.40)             1.61 (1.10--2.36)
    BMI \>40 kg·m^−2^                          49 (47.1%)        2.17 (1.41--3.35)             2.34 (1.51--3.62)
   Concurrent DVT                                                                        
    BMI \<18.5 kg·m^−2^                        3 (10.3%)         0.44 (0.13--1.49)             0.45 (0.13--1.52)
    BMI 18.5--24.9 kg·m^−2^                   102 (20.7%)             1 (ref.)                      1 (ref.)
    BMI 25.0--29.9 kg·m^−2^                   170 (23.7%)        1.19 (0.90--1.57)             1.15 (0.87--1.52)
    BMI 30.0--34.9 kg·m^−2^                   121 (29.3%)        1.58 (1.17--2.15)             1.57 (1.16--2.14)
    BMI 35.0--39.9 kg·m^−2^                    36 (23.4%)        1.17 (0.76--1.80)             1.20 (0.78--1.85)
    BMI \>40 kg·m^−2^                           15 (14%)         0.64 (0.36--1.16)             0.68 (0.38--1.23)
  **Outcomes**                                                                           
   Death                                                                                 
    BMI \<18.5 kg·m^−2^                         1 (3.4%)         1.22 (0.16--9.61)             0.92 (0.11--7.59)
    BMI 18.5--24.9 kg·m^−2^                    14 (2.8%)              1 (ref.)                      1 (ref.)
    BMI 25.0--29.9 kg·m^−2^                    22 (3.1%)         1.08 (0.55--2.14)             1.09 (0.55--2.18)
    BMI 30.0--34.9 kg·m^−2^                    14 (3.4%)         1.20 (0.56--2.54)             1.21 (0.57--2.60)
    BMI 35.0--39.9 kg·m^−2^                     5 (3.2%)         1.15 (0.41--3.23)             1.29 (0.45--3.71)
    BMI \>40 kg·m^−2^                           1 (1.0%)         0.33 (0.04--2.55)             0.53 (0.07--4.18)
   Recurrent VTE                                                                         
    BMI \<18.5 kg·m^−2^                         1 (3.4%)         1.92 (0.24--15.67)            1.90 (0.23--15.57)
    BMI 18.5--24.9 kg·m^−2^                     9 (1.8%)              1 (ref.)                      1 (ref.)
    BMI 25.0--29.9 kg·m^−2^                    21 (2.9%)         1.62 (0.74--3.57)             1.55 (0.70--3.42)
    BMI 30.0--34.9 kg·m^−2^                    14 (3.4%)         1.88 (0.81--4.40)             1.82 (0.78--4.25)
    BMI 35.0--39.9 kg·m^−2^                     2 (1.3%)         0.71 (0.15--3.30)             0.71 (0.15--3.34)
    BMI \>40 kg·m^−2^                           3 (2.9%)         1.59 (0.42--5.99)             1.41 (0.78--2.53)
   Hospitalisation                                                                       
    BMI \<18.5 kg·m^−2^                          0 (0%)                  0                             0
    BMI 18.5--24.9 kg·m^−2^                    16 (3.3%)              1 (ref.)                      1 (ref.)
    BMI 25.0--29.9 kg·m^−2^                    34 (4.7%)         1.48 (0.81--2.72)             1.49 (0.81--2.75)
    BMI 30.0--34.9 kg·m^−2^                    23 (5.6%)         1.75 (0.91--3.37)             1.74 (0.90--3.35)
    BMI 35.0--39.9 kg·m^−2^                    11 (7.1%)         2.29 (1.04--5.04)             2.39 (1.08--5.32)
    BMI \>40 kg·m^−2^                           5 (4.8%)         1.50 (0.54--4.20)             1.99 (0.70--5.67)
   Bleeding                                                                              
    BMI \<18.5 kg·m^−2^                          0 (0%)                  0                             0
    BMI 18.5--24.9 kg·m^−2^                     3 (0.6%)              1 (ref.)                      1 (ref.)
    BMI 25.0--29.9 kg·m^−2^                     7 (1.0%)         1.61 (0.41--6.25)             1.72 (0.44--6.74)
    BMI 30.0--34.9 kg·m^−2^                     9 (2.2%)         3.63 (0.98--13.50)            3.82 (1.02--14.34)
    BMI 35.0--39.9 kg·m^−2^                     8 (5.2%)         8.93 (2.34--34.10)            9.99 (2.56--38.92)
    BMI \>40 kg·m^−2^                           3 (2.9%)         4.84 (0.96--24.33)            7.26 (1.37--38.32)
   All adverse events                                                                    
    BMI \<18.5 kg·m^−2^                         2 (6.9%)         1.23 (0.279--5.43)            1.08 (0.24--4.90)
    BMI 18.5--24.9 kg·m^−2^                    28 (5.7%)              1 (ref.)                      1 (ref.)
    BMI 25.0--29.9 kg·m^−2^                    47 (6.6%)         1.16 (0.72--1.89)             1.15 (0.70--1.87)
    BMI 30.0--34.9 kg·m^−2^                    35 (8.5%)         1.53 (0.92--2.57)             1.50 (0.89--2.52)
    BMI 35.0--39.9 kg·m^−2^                    12 (7.8%)         1.40 (0.69--2.83)             1.47 (0.71--2.94)
    BMI \>40 kg·m^−2^                           7 (6.7%)         1.20 (0.51--2.82)             1.55 (0.65--3.72)

BMI \<18.5 kg·m^−2^, n=29; 18.5--24.9 kg·m^−2^, n=492; 25.0--29.9 kg·m^−2^, n=716; 30.0--34.9 kg·m^−2^, n=413; 35.0--39.9 kg·m^−2^, n=154; \>40 kg·m^−2^, n=104. Ref.: BMI 18.5--24.9 kg·m^−2^. Proportion was calculated per BMI category with follow-up up to 12 months. NT-proBNP: N-terminal pro-brain natriuretic peptide; sPESI: simplified Pulmonary Embolism Severity Index; RV/LV: right ventricular/left ventricular ratio; DVT: deep vein thrombosis; VTE: venous thromboembolism. ^\#^: for age and sex; sPESI only adjusted for sex.

There were 57 deaths, 50 recurrent VTEs, 89 hospitalisations, 30 major bleedings, and 131 adverse events overall reported during 1 year. For the clinical outcomes an exposure--response relation for risk of hospitalisation, bleeding and adverse events was observed, with the risk of the event increasing with BMI ([table 3](#TB3){ref-type="table"}). The highest risk in the BMI category \>40 was for bleeding (OR 7.26, 95% CI 1.37--38.3). Also, for the other clinical outcomes, mortality and recurrent VTE, an increase for the higher BMI categories was observed, as well as for the overall risk of adverse events ([figure 2](#F2){ref-type="fig"}). Interestingly, risk of hospitalisation and major bleeding were not higher in patients who were underweight, although the 95% CI for this point estimate was wide.

Discussion {#s4}
==========

We demonstrated that prognostic characteristics of PE on CTPA are associated with BMI in a category-dependent manner, with the highest risk at the extremes of BMI. Also, for the most important clinical outcomes of mortality and VTE recurrence, an unfavourable trend for the high BMI categories was present, though not statistically significant. Our study highlights the potential importance of assessing BMI as a prognostic indicator when diagnosing and treating patients with PE. Contrary to many other determinants, common demographics such as body size and height are easily obtainable, without any effort or costs, for regular use in daily clinical practice.

A strength of our study is the prospective and rigorous collection of all included data as part of a large international randomised clinical trial. Both imaging data and clinical outcomes were assessed before the data lock and the assessors were blinded for treatment and outcome. We evaluated a broad range of parameters in order to provide a complete, integral picture rather than limiting to a single factor with concurrent restricted impact.

Our study has some limitations. Despite the fact that the number of all included patients is large, the relatively low frequency of events with associated statistical uncertainty prohibits us from drawing firm or definite conclusions, even more so for the underweight category. We did not further adjust for potential confounders like comorbidities and risk factors, as the power to do so was limited by the relatively low number of outcome events. Because of the paucity of literature on this increasingly prominent issue, however, we nevertheless think of it contributing value, as an incentive for further exploration of this topic. Also, we are aware that patients included in a randomised controlled trial do not necessarily reflect all those presenting in daily clinical practice, and our results cannot be unconditionally generalised to those with exclusion criteria for the trial, such as patients who are haemodynamically unstable and patients with a limited life expectancy. Lastly, we only used correlation with BMI categories. Although the use of BMI as an obesity measure has been questioned, it is still the most widely used body weight measurement, and is easy to obtain. Apart from BMI, other measures for body size exist, such as body fat percentage, waist circumference and waist-to-hip ratio (not registered in the trial) \[[@C5]\].

A classic U- or J-shaped curve for BMI categories has been reported in a wide variety of pathological and physiological conditions, such as cardiovascular and respiratory disease, stroke and cancer \[[@C10], [@C13], [@C14]\]. Our findings suggest that a similar pattern applies to prognostic indicators in patients with PE, with the lowest prevalence of many investigated parameters for the normal weight group, and a higher prevalence at the extremes of body weight. BMI not only was predictive in several clinical and radiological prognostic characteristics associated with RV dysfunction, but also in a similar way with the relevant clinical outcomes. We are not aware of other studies that explored the association between a broad range of prognostic characteristics in PE and BMI categories; only one study reported that patients who are obese in general have reduced levels of NT-proBNP, despite higher LV end-diastolic pressures \[[@C15]\]. As such, it is even more interesting that in patients with PE, NT-proBNP levels tended to be higher in higher BMI categories. Notably, in patients who are obese, adaptations in cardiac structure and function, more specifically differences in RV morphology could develop \[[@C16]\]. These alterations could be induced by increased RV afterload, increased blood volume, hormonal effects, or direct obesity-related myocardial effects \[[@C17]\].

How do our findings fit into the current assessment of patients who are overweight with acute PE? In the Framingham study \[[@C18]\], women who had a fatal PE had a higher body weight than those who died of other causes. On the contrary, several investigators have reported a higher incidence of VTE in patients who are obese but a lower rate of mortality compared to patients who are not obese, even despite the fact that patients who are obese have more comorbidities, a phenomenon referred to as the obesity paradox \[[@C19]--[@C23]\]. However, this is also in contrast with large autopsy studies, where in each category of above-normal BMIs, individuals who were obese were more likely to die from PE \[[@C24], [@C25]\].

Complex relationships exist between body mass indicators, metabolic function and cardiovascular risk. Possibly, clot composition in individuals who are obese might be different from those with normal weight \[[@C26]\]. It has been hypothesised that these clots could become more resistant to fibrinolysis because of higher fibrinogen levels, polycythaemia, and other haematological changes related to obesity \[[@C27], [@C28]\]. Our observation that patients with higher BMI categories had more central clots could also be a reflection of the different physical properties of the thrombi in obese.

For recurrent VTE, several papers have been published; however, these have conflicting results, as some found no association between obesity and the risk of VTE recurrence \[[@C29]--[@C32]\], whereas others found a higher recurrence risk with higher BMI \[[@C33], [@C34]\]. In our study, confidence intervals for the estimates crossed unity and we therefore cannot give a definitive answer on this matter.

Reports on the other investigated clinical outcomes (hospitalisation, bleeding and overall adverse effects) are scarce, as most often they are used as a composite outcome, or focus on differences between treatment regimens.

Our finding of a trend for increased hospitalisation for patients who were obese is supported by the large Australian 45 and Up cohort study, where the risk of hospitalisation for a wide range of cardiovascular disease subtypes increased with relatively ﬁne increments in BMI. For PE, the age- and sex-adjusted hazard ratio was 1.39 (95% CI 1.25--1.55) compared to normal BMI \[[@C35]\].

Bleeding complications during treatment of PE are more frequent than recurrent VTE \[[@C36]\]. In the current study a higher incidence of bleeding in the overweight was observed, underlining the importance of this complication. Both for weight and BMI, in the RIETE prospective registry \[[@C19], [@C37]\] as well as in subgroup analysis of the Matisse \[[@C29]\] and EINSTEIN DVT/PE \[[@C31]\] anticoagulation randomised controlled trials no association between body weight or BMI and major bleeding was found. However, analysis was only performed using two or three large categories (patients weighing \<50, 50--100 kg *versus* \>100 kg, or BMI\<30 *versus* ≥30 or \<25, 25--30 and 30--35), and patients who were underweight were included in the normal weight category. Of note, in the RIETE study, patients who were underweight with VTE (or weighing \<50 kg) had a signiﬁcantly higher rate of bleeding complications. This is in contradiction with our findings. A potential explanation could be the difference in selection of patients, or analysis and categorisation study.

For patients who are underweight, studies on other clinical outcomes are scarce. For prognostic characteristics and RVD, no data have been published until now. Patients who are underweight had increased mortality compared to those with normal weight \[[@C19]\], but an equal number of fatal PEs. The difficulty for this category is that it can reflect two different populations, those who have been always underweight, and those that due to an underlying condition sustained significant weight loss, such as in cancer, immobility or renal insufficiency, making them susceptible to adverse events. As these people have less adipose tissue, drug pharmacokinetics are probably different.

Our findings of a trend towards worse prognostics in patients who are obese underlines the importance of more patient-centred care \[[@C38]\], in particular with respect to choosing the appropriate anticoagulant therapy for each individual patient. In this way, we can confirm the call for increased awareness on dedicated prophylactic and therapeutic anticoagulant regimens in obesity \[[@C7]\]. Reassuringly, a recent well-sized cohort study suggested similar efficacy and safety between direct oral anti-Xa inhibitors and warfarin in patients who are morbidly obese, although these retrospective findings warrant confirmation in prospective studies \[[@C39]\].

Future directions for study should explore the interaction of obesity and other risk factors for VTE, both for development, presentation, therapeutics and outcomes \[[@C40]\]. Special attention should focus on clinical severity, RVD and risk stratification. As obesity can be regarded a proinflammatory condition, more fundamental research should be directed towards molecular, pathogenic and sex-specific mechanisms responsible for VTE onset, development, and recurrence \[[@C41]\].

In conclusion, we found that several clinical and radiological prognostics characteristics and RVD in PE are not evenly distributed among BMI categories. This is reflected in a trend towards worse outcomes in the patients who are overweight and underweight compared to normal weights. This could be an incentive towards dedicated patient-tailored evaluation and treatment.
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